A phase I prospective, single dose, double blinded, parallel group pharmacokinetic study of TX16 biosimilar product TX16.
Phase of Trial: Phase I
Latest Information Update: 23 Feb 2018
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary)
- Indications Colorectal cancer
- Focus Pharmacokinetics
- 23 Feb 2018 New trial record
- 17 Jan 2018 According to a Tanvex BioPharma media release, the company has completed the trial last year.
- 19 Dec 2017 Primary endpoint AUC 0-infinity has been met, according to Tanvex BioPharma media release.